Considering that this drug was well-tolerated, lowered granulocyte IGF1R expression, increased serum IGF1 levels, and reduced the tumor burden in 9 of 27 patients143, further exploration of its efficacy may hold promise for T-ALL patients. This evidence concerns the gene IGF1R and acute lymphoblastic leukemia.